JP2018520093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520093A5 JP2018520093A5 JP2017558027A JP2017558027A JP2018520093A5 JP 2018520093 A5 JP2018520093 A5 JP 2018520093A5 JP 2017558027 A JP2017558027 A JP 2017558027A JP 2017558027 A JP2017558027 A JP 2017558027A JP 2018520093 A5 JP2018520093 A5 JP 2018520093A5
- Authority
- JP
- Japan
- Prior art keywords
- syringe
- subject
- kinase inhibitor
- injectable composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007972 injectable composition Substances 0.000 claims 17
- 229940043355 kinase inhibitor Drugs 0.000 claims 13
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 10
- 208000030533 eye disease Diseases 0.000 claims 9
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 5
- -1 radatinib Chemical compound 0.000 claims 5
- 229960003787 sorafenib Drugs 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- 201000004569 Blindness Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 229960003982 apatinib Drugs 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 229960002412 cediranib Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229950002216 linifanib Drugs 0.000 claims 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229950003968 motesanib Drugs 0.000 claims 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical group C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 229960001131 ponatinib Drugs 0.000 claims 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910001220 stainless steel Inorganic materials 0.000 claims 1
- 239000010935 stainless steel Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157257P | 2015-05-05 | 2015-05-05 | |
| US62/157,257 | 2015-05-05 | ||
| PCT/US2016/030912 WO2016179357A1 (en) | 2015-05-05 | 2016-05-05 | Injectable depot formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520093A JP2018520093A (ja) | 2018-07-26 |
| JP2018520093A5 true JP2018520093A5 (enExample) | 2019-06-13 |
Family
ID=57218334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558027A Pending JP2018520093A (ja) | 2015-05-05 | 2016-05-05 | 注射可能なデポー製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160324836A1 (enExample) |
| EP (1) | EP3291812B1 (enExample) |
| JP (1) | JP2018520093A (enExample) |
| CN (1) | CN107530334A (enExample) |
| AU (1) | AU2016258001B2 (enExample) |
| BR (1) | BR112017023762A2 (enExample) |
| CA (1) | CA2984637A1 (enExample) |
| MX (1) | MX385405B (enExample) |
| RU (1) | RU2017137763A (enExample) |
| WO (1) | WO2016179357A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
| CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| CN114245737A (zh) * | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| CN101890018B (zh) * | 2009-05-22 | 2014-06-18 | 中国科学院化学研究所 | 一种酪氨酸蛋白激酶抑制剂及其制备方法 |
| WO2013000909A1 (en) * | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
| CN104204804B (zh) * | 2011-11-11 | 2016-09-28 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| AR089248A1 (es) * | 2011-12-14 | 2014-08-06 | Abbvie Inc | Composiciones que contienen inhibidores de quinasas |
-
2016
- 2016-05-05 US US15/147,198 patent/US20160324836A1/en not_active Abandoned
- 2016-05-05 JP JP2017558027A patent/JP2018520093A/ja active Pending
- 2016-05-05 AU AU2016258001A patent/AU2016258001B2/en active Active
- 2016-05-05 EP EP16790066.1A patent/EP3291812B1/en active Active
- 2016-05-05 CN CN201680025439.7A patent/CN107530334A/zh active Pending
- 2016-05-05 CA CA2984637A patent/CA2984637A1/en not_active Abandoned
- 2016-05-05 WO PCT/US2016/030912 patent/WO2016179357A1/en not_active Ceased
- 2016-05-05 RU RU2017137763A patent/RU2017137763A/ru not_active Application Discontinuation
- 2016-05-05 BR BR112017023762-8A patent/BR112017023762A2/pt not_active Application Discontinuation
- 2016-05-05 MX MX2017014084A patent/MX385405B/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520093A5 (enExample) | ||
| PH12017500844B1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| RU2013112353A (ru) | Фосфолипидный депо-препарат | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| WO2018022815A3 (en) | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug | |
| ES2706059T3 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y derivado de L-arginina y una inyección que incluye la composición | |
| JP2014129360A5 (enExample) | ||
| RU2017137763A (ru) | Депо-составы для инъекций | |
| HRP20191366T4 (hr) | Injekcijski pripravak | |
| SG11201707448SA (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| HRP20220066T1 (hr) | Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2015007136A5 (enExample) | ||
| BR112016001544A2 (pt) | composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas | |
| JP2018532806A5 (enExample) | ||
| JP2018538243A5 (enExample) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| JP6931257B2 (ja) | レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法 | |
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| EA035764B1 (ru) | Офтальмологическая фармацевтическая композиция | |
| MX2021011727A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| RU2017107495A (ru) | 2,2,2-трифторэтил-тиадиазины |